8 studies found for:    e5508
Show Display Options
Rank Status Study
1 Recruiting Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
Condition: Lung Cancer
Interventions: Biological: bevacizumab;   Drug: pemetrexed disodium
2 Completed Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).
Conditions: Venous Thromboembolism;   Deep Vein Thrombosis;   Pulmonary Embolism;   Thromboembolism;   Venous Thrombosis
Interventions: Drug: edoxaban tosylate(DU-176b);   Drug: low molecular weight heparin/unfractionated heparin;   Drug: warfarin
3 Recruiting Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Exenatide Once Weekly;   Drug: Placebo
4 Completed
Has Results
Tipranavir/Ritonavir vs. Genotypically Defined Protease Inhibitor/Ritonavir in HIV Patients (RESIST-2)
Condition: HIV Infections
Interventions: Drug: Tipranavir (with low dose ritonavir);   Drug: Comparator protease inhibitor(CPI)/low dose ritonavir(r)
5 No longer available An Open Label Safety Study of Tipranavir Co-administered With Low-dose Ritonavir in Patients With Advanced HIV-1 Infection and Limited Treatment Options.
Condition: HIV Infections
Intervention: Drug: Tipranavir
6 Terminated
Has Results
Interventional Management of Stroke (IMS) III Trial
Condition: Stroke
Interventions: Drug: IV rt-PA alone;   Other: endovascular therapy
7 Completed
Has Results
Rollover Trial Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV 1 Infected Subjects
Condition: HIV Infections
Intervention: Drug: Tipranavir
8 Active, not recruiting A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple Sclerosis
Condition: Relapsing Multiple Sclerosis
Intervention: Drug: Laquinimod

Indicates status has not been verified in more than two years